The development of pediatric oncologists and pediatric oncology nurses who are highly trained in clinical research is essential for continued progress to be made in the treatment of childhood cancer. This proposal describes a Pediatric Oncology Clinical Research Training Program, developed by Baylor College of Medicine's Texas Children's Cancer Center, that is structured to provide a formal, comprehensive, multidisciplinary clinical research educational program that will train board eligible pediatric oncologists who have completed a three year fellowship and Ph.D.-prepared ontology nurses in the design, implementation and analysis of all phases of clinical research trials. Trainees will spend a portion of their first year participating in a core curriculum in clinical research and spend the remainder of that and subsequent year(s) receiving further clinical research training in their choice of one of five specialized training tracks (clinical pharmacology, neuro-oncology cell and gene therapy, leukemia or solid tumors). This carefully mentored training program will take advantage of BCM's funded (NIH-K30 award) Clinical Scientist Training Program to provide a comprehensive, didactic clinical research core curriculum that will serve as a foundation for further training within one of the five specialized areas of research. The research experience within each of these areas will be tailored to meet the individual trainee's long-term research goals. It will provide mentorship by both a laboratory and clinical mentor' while providing in depth exposure to the most important facets of the clinical research process. Trainees will be instructed in clinical trial design, statistical analysis, research ethics and regulatory requirements and guidelines. In addition, under the tutelage of experienced mentors, trainees will design and conduct clinical trials in their respective areas of focus and will learn by mentor modeling the uniquely interactive, collaborative skills necessary to successfully develop effective clinical trials. Because trainees who complete this program will be well-grounded in both in the basic biology of their particular specialty areas and translational research skills, they will be well suited to become future leaders in pediatric oncology clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA090433-04
Application #
6919308
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
2002-07-01
Project End
2007-06-30
Budget Start
2005-07-08
Budget End
2006-06-30
Support Year
4
Fiscal Year
2005
Total Cost
$756,000
Indirect Cost
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Kilburn, Lindsay B; Kocak, Mehmet; Baxter, Patricia et al. (2018) A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 65:
Stevens, Alexandra M; Miller, Jennifer M; Munoz, Jaime O et al. (2017) Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv 1:1387-1397
Heczey, Andras; Louis, Chrystal U; Savoldo, Barbara et al. (2017) CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther 25:2214-2224
Rau, Rachel E; Carroll, Andrew J; Heerema, Nyla A et al. (2017) Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. Br J Haematol 179:843-846
Cooper, Todd M; Sison, Edward Allan Racela; Baker, Sharyn D et al. (2017) A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co Pediatr Blood Cancer 64:
Flores, Ricardo J; Kelly, Aaron J; Li, Yiting et al. (2017) The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma. Pediatr Blood Cancer 64:
Flores, Ricardo J; Kelly, Aaron J; Li, Yiting et al. (2017) A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG. Cancer 123:144-154
Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81
Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-934

Showing the most recent 10 out of 65 publications